MHY-1685

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

MHY-1685 

MHY-1685 是一个新的 mTOR 抑制剂,为改善基于 hCSC 的心肌再生提供了机会。

MHY-1685

MHY-1685 Chemical Structure

CAS No. : 27406-31-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, provides opportunities to improve hCSC-based myocardial regeneration.

分子量

232.19

Formula

C11H8N2O4

CAS 号

27406-31-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Park JH, et al. Human cardiac stem cells rejuvenated by modulating autophagy with MHY-1685 enhance the therapeutic potential for cardiac repair. Exp Mol Med. 2021 Sep;53(9):1423-1436.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

MHY-1685

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

MHY-1685 

MHY-1685 是一个新的 mTOR 抑制剂,为改善基于 hCSC 的心肌再生提供了机会。

MHY-1685

MHY-1685 Chemical Structure

CAS No. : 27406-31-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, provides opportunities to improve hCSC-based myocardial regeneration.

分子量

232.19

Formula

C11H8N2O4

CAS 号

27406-31-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Park JH, et al. Human cardiac stem cells rejuvenated by modulating autophagy with MHY-1685 enhance the therapeutic potential for cardiac repair. Exp Mol Med. 2021 Sep;53(9):1423-1436.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

MHY-1685

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

MHY-1685 

MHY-1685 是一个新的 mTOR 抑制剂,为改善基于 hCSC 的心肌再生提供了机会。

MHY-1685

MHY-1685 Chemical Structure

CAS No. : 27406-31-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, provides opportunities to improve hCSC-based myocardial regeneration.

分子量

232.19

Formula

C11H8N2O4

CAS 号

27406-31-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Park JH, et al. Human cardiac stem cells rejuvenated by modulating autophagy with MHY-1685 enhance the therapeutic potential for cardiac repair. Exp Mol Med. 2021 Sep;53(9):1423-1436.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

MHY908

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

MHY908 

MHY908 是 PPARα 和 PPARγ 的有效双重激动剂。MHY908 还通过抑制蘑菇酪氨酸酶活性抑制黑色素生成。

MHY908

MHY908 Chemical Structure

CAS No. : 1393371-39-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

MHY908 is a potent dual agonist of PPARα and PPARγ[1]. MHY908 also inhibits melanogenesis through inhibition of mushroom tyrosinase activity[2].

分子量

347.82

Formula

C17H14ClNO3S

CAS 号

1393371-39-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Park MH, et al. Potent anti-diabetic effects of MHY908, a newly synthesized PPAR α/γ dual agonist in db/db mice. PLoS One. 2013 Nov 14;8(11):e78815.

    [2]. Park MH, et al. Inhibition of melanogenesis by 2-[4-(5-chlorobenzo[d]thiazol-2-yl)phenoxy]-2-methylpropanoic acid (MHY908). Arch Pharm Res. 2015 Apr;38(4):505-11.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

MHY1485

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

MHY1485  纯度: 99.86%

MHY1485 是一种有效的细胞渗透性 mTOR 激活剂,靶向 mTOR 的 ATP 结构域。MHY 1485 通过抑制自噬体和溶酶体之间的融合来抑制自噬 (autophagy)。

MHY1485

MHY1485 Chemical Structure

CAS No. : 326914-06-1

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥500 In-stock
5 mg ¥400 In-stock
10 mg ¥700 In-stock
50 mg ¥2500 In-stock
100 mg ¥4000 In-stock
200 mg ¥5800 In-stock
500 mg   询价  
1 g   询价  

* Please select Quantity before adding items.

MHY1485 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Kinase Inhibitor Library
  • PI3K/Akt/mTOR Compound Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Anti-Aging Compound Library
  • Antioxidants Compound Library
  • Oxygen Sensing Compound Library
  • Glycolysis Compound Library
  • Cytoskeleton Compound Library
  • Glutamine Metabolism Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Cancer Metabolism Compound Library
  • Angiogenesis Related Compound Library
  • Lipid Metabolism Compound Library
  • Glucose Metabolism Compound Library

生物活性

MHY1485 is a potent cell-permeable mTOR activator that targets the ATP domain of mTOR. MHY1485 inhibits autophagy by suppression of fusion between autophagosomes and lysosomes[1].

IC50 & Target

mTORC1

 

mTORC2

 

Autophagy

 

体外研究
(In Vitro)

MHY1485 (10 μM; 4 hours) shows that GCDC-induced autophagic activity is inhibited by upregulating p-mTOR expression and downregulating LC3 and p62 expression in HCC cells[1].
MHY1485 (5 μM; 6 hours) increases the LC3II/LC3I ratio in a dose and time-dependently manner due to presumably inhibited LC3II degradation in rat liver Ac2F cells[2].
MHY1485 (0.5-2 μM; 6 hours) increases the phosphorylation of mTOR at ser2448 and upregulates the level of phosphorylation of 4E-BP1 in a dose-dependently manner in Ac2F cells[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: HCC cells
Concentration: 10 μM
Incubation Time: 4 hours
Result: Upregulated p-mTOR and downregulated LC3 and p62 expression.

体内研究
(In Vivo)

MHY1485 (intraperitoneal injection; 10 mg/kg, 2 days) blocks the autophagy signaling induced by follicle-stimulating hormone (FSH). It increases p-mTOR and p-S6K1 expression levels, whereas LC3 expression shows no marked change compared to that in the control group[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 4-week-old female ICR mice[3]
Dosage: 10 mg/kg, 2 days
Administration: Intraperitoneal injection
Result: Suppressed the autophagy level following FSH treatment. 

分子量

387.39

Formula

C17H21N7O4

CAS 号

326914-06-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 7.69 mg/mL (19.85 mM; Need ultrasonic)

H2O : 1 mg/mL (2.58 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.5814 mL 12.9069 mL 25.8138 mL
5 mM 0.5163 mL 2.5814 mL 5.1628 mL
10 mM 0.2581 mL 1.2907 mL 2.5814 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 0.77 mg/mL (1.99 mM); Clear solution

    此方案可获得 ≥ 0.77 mg/mL (1.99 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 7.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 0.77 mg/mL (1.99 mM); Clear solution

    此方案可获得 ≥ 0.77 mg/mL (1.99 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 7.7 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Gao L, et al. Glycochenodeoxycholate promotes hepatocellular carcinoma invasion and migration by AMPK/mTOR dependent autophagy activation. Cancer Lett. 2019 Jul 10;454:215-223.

    [2]. Choi YJ, et al. Inhibitory effect of mTOR activator MHY1485 on autophagy: suppression of lysosomal fusion. PLoS One. 2012;7(8):e43418.

    [3]. Zhou J, et al.Administration of follicle-stimulating hormone induces autophagy via upregulation of HIF-1α in mouse granulosa cells.Cell Death Dis. 2017 Aug 17;8(8):e3001.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务